Recently approved therapies in acute myeloid leukemia: a complex treatment landscape

Acute myeloid leukemia (AML) is a heterogeneous disease with multiple molecular pathways driving its progression [1,2]. It is a clonal hematopoietic disorder characterized by uncontrolled proliferation without differentiation of myeloid progenitors [3]. With an approximate 5-year survival rate of 27%, AML has a particularly poor prognosis and is rapidly fatal if left untreated [4].
Source: Leukemia Research - Category: Hematology Authors: Source Type: research